Literature DB >> 8925273

Metabolic and functional mapping of the neural network subserving inferior collicular seizure generalization.

T J McCown1, G E Duncan, K B Johnson, G R Breese.   

Abstract

The sensory-motor portion of the inferior collicular cortex is capable of seizure genesis that is characterized initially by coincident wild running behaviors and localized electrographic afterdischarge. With repeated stimulations, this seizure activity spreads into the forebrain, producing generalized tonic-clonic or myoclonic seizure activity. In order to characterize the neural network subserving this caudal-rostral seizure generalization, three mapping techniques were used: 2-deoxyglucose (2-DG) utilization, c-fos expression and local anesthetic microinjection. Kindled seizure generalization from the inferior collicular cortex produced a global increase in 2-DG accumulation, while relative 2-DG increases were found in the inferior collicular cortex, dorsal lateral lemniscus, dorsal central gray, peripeduncular nucleus, medial geniculate nucleus, substantia nigra, entopeduncular nucleus, ventroposterior and centromedian thalamus and tenia tectum, as well as the perirhinal, somatosensory and frontal cortices. Kindled seizure generalization also increased c-fos-like immunoreactivity (FLI) in the inferior collicular cortex, cuneiform nucleus, dorsal lateral nucleus of the lateral lemniscus, peripeduncular nucleus, caudal central gray, dentate gyrus of the hippocampus, rhinal fissure area of the perirhinal cortex and the frontal cortex. Microinjections of procaine into the amygdala, perirhinal cortex, entopeduncular nucleus, substantia nigra, peripeduncular nucleus, dorsal central gray, and pontine reticular nucleus all prevented generalized seizure behaviors, but had no effect on the wild running seizures. Conversely, procaine microinjection into the area of the cuneiform nucleus/pedunculopontine tegmental nucleus prevented the wild running seizure but did not block the generalized seizure activity. Neither wild running, nor generalized seizures were altered following procaine microinjections into the anterior thalamus, sub-thalamus, lateral hypothalamus, hippocampus or deep superior colliculus. Thus, specific forebrain sites form a widespread neural network that mediates the generalization of seizure activity from the inferior collicular cortex into the forebrain.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8925273     DOI: 10.1016/0006-8993(95)00970-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  5 in total

1.  Spatiotemporal differences in the c-fos pathway between C57BL/6J and DBA/2J mice following flurothyl-induced seizures: A dissociation of hippocampal Fos from seizure activity.

Authors:  Sridhar B Kadiyala; Dominick Papandrea; Karina Tuz; Tara M Anderson; Sachidhanand Jayakumar; Bruce J Herron; Russell J Ferland
Journal:  Epilepsy Res       Date:  2014-11-22       Impact factor: 3.045

2.  Electric field strength and focality in electroconvulsive therapy and magnetic seizure therapy: a finite element simulation study.

Authors:  Zhi-De Deng; Sarah H Lisanby; Angel V Peterchev
Journal:  J Neural Eng       Date:  2011-01-19       Impact factor: 5.379

Review 3.  Brain mechanisms of altered conscious states during epileptic seizures.

Authors:  Andrea Eugenio Cavanna; Francesco Monaco
Journal:  Nat Rev Neurol       Date:  2009-05       Impact factor: 42.937

4.  Focal BOLD fMRI changes in bicuculline-induced tonic-clonic seizures in the rat.

Authors:  Matthew N DeSalvo; Ulrich Schridde; Asht M Mishra; Joshua E Motelow; Michael J Purcaro; Nathan Danielson; Xiaoxiao Bai; Fahmeed Hyder; Hal Blumenfeld
Journal:  Neuroimage       Date:  2010-01-14       Impact factor: 6.556

5.  Cortical and subcortical networks in human secondarily generalized tonic-clonic seizures.

Authors:  H Blumenfeld; G I Varghese; M J Purcaro; J E Motelow; M Enev; K A McNally; A R Levin; L J Hirsch; R Tikofsky; I G Zubal; A L Paige; S S Spencer
Journal:  Brain       Date:  2009-04-01       Impact factor: 13.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.